Table of Contents
TORONTO — Shoppers Drug Mart has agreed to a commercial partnership with San Diego, Calif.-based blood testing startup Truvian Health. Truvian has created a printer-sized device that enables practitioners to perform a blood test in less than 40 minutes without sending the sample to a different lab.
Truvian announced an injection of $74 million of capital to be used in part to secure US Food and Drug Administration (FDA) clearance for its blood testing platform.
As a part of the round, Shoppers Drug Mart, Canada’s largest pharmacy, joins Truvian as a commercial partner. “Working with our government partners, we believe in advancing technology to better support patient care, including comprehensive blood testing,” said Jeff Leger, president at Shoppers Drug Mart. “Truvian’s novel platform, combined with the convenience of accessing care in pharmacy, will be an amazing step forward in making care more accessible and convenient for patients.”
Late last year, Shoppers Drug Mart led an onsite evaluation of Truvian which compared results from Truvian’s platform to a traditional central laboratory. Results between Truvian and the central laboratory were concordant, emphasizing the potential utility of Truvian’s solution.
“These new investments and strategic partnerships further validate our goal to bring convenient, comprehensive testing to primary care, enabling patients and their doctors to make timely decisions affecting their health,” said Jay Srinivasan, chief executive officer of Truvian. “We are on the cusp of delivering what the world needs to counter today’s non-communicable disease burden and unsustainable healthcare costs.”
Truvian is the first company to share evidence that demonstrates a multi-modal platform can achieve clinical performance equivalent to the central laboratory across a large panel of tests with a single sample. To date, Truvian’s integrated platform has been evaluated on more than 50,000 samples across 5,000 donors while achieving a platform run reliability rate of greater than 98%. Truvian has also scaled its instrument and consumable manufacturing capabilities to initiate its clinical trials and early partner access programs.
